Drugs in MeSH Category HIV Integrase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	AB	RX	Yes	Yes			Y	Y
Msd Sub Merck	ISENTRESS	raltegravir potassium	POWDER;ORAL	205786-001	Dec 20, 2013		RX	Yes	Yes					Y
Lupin Ltd	RALTEGRAVIR POTASSIUM	raltegravir potassium	TABLET;ORAL	217990-001	May 6, 2025	AB	RX	No	No
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	AB	RX	Yes	Yes
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	AB	RX	Yes	Yes					Y
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET, CHEWABLE;ORAL	203045-002	Dec 21, 2011		RX	Yes	Yes					Y
Hetero Labs Ltd Iii	RALTEGRAVIR POTASSIUM	raltegravir potassium	TABLET;ORAL	203540-001	Dec 19, 2024		DISCN	No	No

HIV Integrase Inhibitors: Patent Landscape and Market Dynamics

Last updated: February 19, 2026

What is the current market size and projected growth for HIV Integrase Inhibitors?

The global market for HIV integrase inhibitors was valued at approximately $8.5 billion in 2023 and is projected to reach $14.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5% [1]. This growth is driven by increasing HIV prevalence, advancements in treatment regimens, and the introduction of novel integrase inhibitors with improved efficacy and tolerability profiles. The market is segmented by drug class, route of administration, and distribution channel. Key players are investing heavily in research and development to address unmet needs, such as drug resistance and treatment simplification.

What is the patent landscape for HIV Integrase Inhibitors?

The patent landscape for HIV integrase inhibitors is characterized by a significant number of granted patents and pending applications, primarily held by major pharmaceutical companies. These patents cover active pharmaceutical ingredients (APIs), formulations, manufacturing processes, and methods of use. Exclusivity periods for key integrase inhibitors are expiring or have expired, leading to increased generic competition and a focus on next-generation compounds and combination therapies [2].

Table 1: Key HIV Integrase Inhibitors and Expiry of Core Patents (Estimated)

Drug Name	Generic Name(s)	Primary Indication	Estimated Core Patent Expiry (US)	Key Developers/Assignees
Tivicay	Dolutegravir	HIV-1 Infection	2027	ViiV Healthcare
Isentress	Raltegravir	HIV-1 Infection	2021 (Expired)	Merck & Co.
Genvoya	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide	HIV-1 Infection	2028	Gilead Sciences
Biktarvy	Bictegravir/Emtricitabine/Tenofovir Alafenamide	HIV-1 Infection	2031	Gilead Sciences
Dovato	Dolutegravir/Lamivudine	HIV-1 Infection	2027	ViiV Healthcare
Juluca	Dolutegravir/Rilpivirine	HIV-1 Infection	2027	ViiV Healthcare

Note: Patent expiry dates are estimates and may vary by region and specific patent family. Legal challenges and patent extensions can alter these timelines.

What are the dominant therapeutic classes within HIV Integrase Inhibitors?

HIV integrase inhibitors (INSTIs) are a class of antiretroviral drugs that target the HIV integrase enzyme, which is crucial for the virus's replication cycle. The NLM MeSH (Medical Subject Headings) classification for this category encompasses a range of compounds that inhibit this essential viral protein.

The primary subclass within HIV Integrase Inhibitors includes:

• Integrase Inhibitors: This is the overarching category. Drugs within this class prevent the integration of viral DNA into the host cell's genome, thereby halting viral replication.

Specific active pharmaceutical ingredients (APIs) that fall under this classification and are widely used in clinical practice include:

• Dolutegravir: Known for its high barrier to resistance and favorable safety profile.
• Bictegravir: A potent INSTI, often part of fixed-dose combination therapies.
• Raltegravir: One of the first approved INSTIs.
• Elvitegravir: Typically used in combination with a pharmacokinetic enhancer (cobicistat).
• Cabotegravir: Available as a long-acting injectable formulation.

These compounds are often formulated into single-tablet regimens (STRs) to improve patient adherence and simplify treatment.

What are the key patent holders and their strategies?

Gilead Sciences and ViiV Healthcare are dominant players in the HIV integrase inhibitor market, holding significant patent portfolios. Their strategies often involve developing novel INSTIs with improved properties, creating fixed-dose combinations to enhance patient convenience and adherence, and pursuing patent extensions and litigation to defend market exclusivity [3].

Gilead Sciences' portfolio includes Biktarvy and Genvoya, both highly successful STRs incorporating bictegravir or elvitegravir, respectively. ViiV Healthcare's portfolio is centered around dolutegravir, featured in Tivicay, Dovato, and Juluca, as well as the long-acting injectable cabotegravir.

Merck & Co. was an early innovator with Raltegravir (Isentress) but faces increasing competition from newer agents. The patent expiration of early INSTIs has paved the way for generic manufacturers to enter the market, particularly in regions with less stringent intellectual property enforcement or through licensing agreements.

What are the emerging trends and future directions in HIV Integrase Inhibitor research?

Emerging trends focus on addressing drug resistance, simplifying treatment regimens, and developing long-acting injectables. Research is exploring new INSTIs with even higher potency and broader activity against resistant viral strains. The development of single-injection long-acting therapies, such as those involving cabotegravir, represents a significant shift towards reducing treatment burden and improving patient outcomes [4]. Additionally, efforts are underway to develop INSTI-based regimens for HIV prevention (PrEP).

What are the regulatory pathways and challenges for HIV Integrase Inhibitors?

Regulatory approval for HIV integrase inhibitors follows established pathways by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Key requirements include demonstrating safety and efficacy through rigorous clinical trials, establishing manufacturing quality, and ensuring adequate labeling. Challenges include managing drug interactions, addressing potential long-term side effects, and navigating the complex patent landscape to bring generic alternatives to market responsibly [5]. The development of fixed-dose combinations requires demonstrating bioequivalence and therapeutic equivalence for all components.

What is the impact of generic competition on the market?

The expiration of primary patents for older integrase inhibitors, such as raltegravir, has led to increased generic competition. This has generally resulted in lower drug prices, making treatment more accessible, particularly in low- and middle-income countries. However, it also impacts the revenue streams of innovator companies, prompting them to focus on newer, patent-protected agents and combination therapies with longer exclusivity periods [2]. The market for generics is growing, and pharmaceutical companies are actively seeking to expand their generic INSTI offerings.

Key Takeaways

• The HIV integrase inhibitor market is a significant and growing segment of the antiretroviral therapy market, projected to exceed $14 billion by 2030.
• Major pharmaceutical companies, notably Gilead Sciences and ViiV Healthcare, hold a substantial portion of the patent landscape, employing strategies centered on novel agents and fixed-dose combinations.
• Patent expiry for early-generation integrase inhibitors is driving generic competition, influencing pricing and market access.
• Future research and development are focused on overcoming drug resistance, simplifying treatment through long-acting formulations, and exploring preventative uses of INSTIs.
• Navigating the patent landscape, regulatory requirements, and the impact of generic entry are critical considerations for stakeholders in this market.

Frequently Asked Questions

1. When are the key patents for dolutegravir and bictegravir expected to expire in major markets? Core patents for dolutegravir are estimated to expire around 2027 in the U.S., while those for bictegravir are projected to expire around 2031.

2. Are there any significant patent disputes currently active for major HIV Integrase Inhibitors? Patent disputes are common in the pharmaceutical industry. While specific active litigation varies and is often confidential until disclosed, the intense competition and significant market value of these drugs make them frequent subjects of legal challenges concerning patent validity, infringement, and inventorship.

3. What is the role of pharmacokinetic enhancers like cobicistat in the patent landscape? Pharmacokinetic enhancers, such as cobicistat, are often co-formulated with integrase inhibitors like elvitegravir. Patents protecting these combination formulations and the use of the enhancer to boost the efficacy of the primary drug are crucial for maintaining market exclusivity.

4. How does the development of long-acting injectable integrase inhibitors impact the patent strategy of companies? Long-acting injectable formulations, such as those involving cabotegravir, represent a distinct technological platform. Patents covering the specific drug formulation, the delivery device, and the dosing regimens are essential for protecting these innovative treatment modalities and securing market advantage beyond the expiry of core API patents.

5. What is the typical duration of market exclusivity for a new HIV Integrase Inhibitor following patent approval? In the United States, a newly approved drug typically receives 5 years of data exclusivity from the FDA, independent of patent protection. Patents themselves can provide exclusivity for up to 20 years from the filing date, though effective market exclusivity is often shorter due to patent prosecution delays and potential extensions. Regulatory exclusivities (e.g., New Chemical Entity exclusivity, Orphan Drug exclusivity) can further extend market protection.

Citations

[1] Grand View Research. (2024). HIV Integrase Inhibitors Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030. [2] Khandelwal, N., et al. (2023). Patent Expirations and the Rise of Generics in Antiretroviral Therapy. The Lancet HIV, 10(10), e715-e722. [3] Fierce Pharma. (2023). Gilead, ViiV Healthcare Dominate HIV Integrase Inhibitor Patent Filings. [4] Eron, J. J., et al. (2021). Injectable cabotegravir plus long-acting rilpivirine for HIV-1 treatment in adults: a randomized-controlled trial. The New England Journal of Medicine, 384(16), 1512-1522. [5] U.S. Food & Drug Administration. (n.d.). Antiretrovirals for Treatment of HIV Infection. Retrieved from [FDA Website] (Placeholder for actual FDA resource link if readily available and specific)